Compare AstraZeneca plc (AZN) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Okta, Inc. — how do they compare? AstraZeneca plc trades at $158.62 (market cap $248.14B), while Okta, Inc. trades at $148.4 (market cap $26.13B). The key difference: AstraZeneca plc is far larger — about 9.5× Okta, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| AZN | OKTA | |
|---|---|---|
Market Cap | $248.14B | $26.13B |
Sector | Health | Technology |
52-Week High | $209.48 | $154.62 |
52-Week Low | $147.06 | $62.93 |
Enterprise Value | $275.41B | $23.95B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Okta trades at $150.04, down 0.48% today, near its pivot point of $150 with bullish moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations. Revenue growth is robust, rising to $2.61B in 2025, while the firm achieved GAAP profitability with net income of $28M, a significant turnaround from prior losses. Recent news highlights Okta's acquisition of Permiso Security to enhance AI-driven identity threat detection, positioning it in the expanding cybersecurity market.
Outlook is positive with analyst consensus at Buy (72.55%) and a $129.71 price target, though current price exceeds this. Opportunities include sustained revenue growth and margin expansion, while risks involve high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Institutional activity shows mixed signals, with some funds increasing stakes amid the stock's 55.6% YTD gain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
